60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Days Sales Outstanding : 133.62 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is 60 Degrees Pharmaceuticals Days Sales Outstanding?

60 Degrees Pharmaceuticals's average Accounts Receivable for the three months ended in Dec. 2023 was $0.18 Mil. 60 Degrees Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.13 Mil. Hence, 60 Degrees Pharmaceuticals's Days Sales Outstanding for the three months ended in Dec. 2023 was 133.62.

The historical rank and industry rank for 60 Degrees Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

SXTP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 143.76 Med: 157.62 Max: 199.03
Current: 179.05

During the past 4 years, 60 Degrees Pharmaceuticals's highest Days Sales Outstanding was 199.03. The lowest was 143.76. And the median was 157.62.

SXTP's Days Sales Outstanding is ranked worse than
81.41% of 893 companies
in the Biotechnology industry
Industry Median: 73.24 vs SXTP: 179.05

60 Degrees Pharmaceuticals's Days Sales Outstanding increased from Dec. 2022 (0.00) to Dec. 2023 (133.62).

Warning Sign:

If a company's sales outstanding increases, it means it has difficulty collecting payments from its customers.

60 Degrees Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for 60 Degrees Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

60 Degrees Pharmaceuticals Days Sales Outstanding Chart

60 Degrees Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

143.76

158.11

157.13

199.03

60 Degrees Pharmaceuticals Quarterly Data
	Dec20	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial						-	346.21	158.17	235.28	133.62

Competitive Comparison of 60 Degrees Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, 60 Degrees Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

60 Degrees Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 60 Degrees Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where 60 Degrees Pharmaceuticals's Days Sales Outstanding falls into.

60 Degrees Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

60 Degrees Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.046	+	0.231)	/	2 )	/	0.254	*	365
=	0.1385					/	0.254	*	365
=	199.03

60 Degrees Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0.138	+	0.231)	/	2 )	/	0.126	*	365 / 4
=	0.1845					/	0.126	*	365 / 4
=	133.62

60 Degrees Pharmaceuticals (NAS:SXTP) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

60 Degrees Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of 60 Degrees Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

60 Degrees Pharmaceuticals (60 Degrees Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 60 Degrees Pharmaceuticals Inc (NAS:SXTP) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

1025 Connecticut Avenue NW, Suite 1000, Washington, D.C, WA, USA, 20036

Website

https://www.60degreespharma.com

60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases through Arakoda and Celgosivir.

Executives

Charles W Allen	director	1881 N. NASH STREET, UNIT 701, ARLINGTON VA 22209
Kentucky Technology Inc.	10 percent owner	824 BULL LEA RUN, SUITE 2100, LEXINGTON KY 40511
Cheryl Xu	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Paul Field	director	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Tyrone Miller	officer: Chief Financial Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Geoffrey S Dow	director, 10 percent owner, officer: CEO and President	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Florida State University Research Foundation Inc.	10 percent owner	200 LEVY AVENUE, BUILDING A, SUITE 351, TALLAHASSEE FL 32310
Bryan Lee Smith	officer: Chief Medical Officer	1025 CONNECTICUT AVENUE NW, SUITE 1000, WASHINGTON DC 20036
Stephen Toovey	director	1025 CONNECTICUT AVENUE NW, SUITE 100, WASHINGTON DC 20036